ESC 2024 | TRI.Fr: Transcatheter Tricuspid Repair for the Treatment of Tricuspid Regurgitation

Right-sided heart failure and tricuspid regurgitation (TR) are associated with poor quality of life and an increased risk of hospitalization and mortality. The aim of this study was to assess the safety and efficacy of tricuspid transcatheter edge-to-edge repair (T-TEER) combined with optimal medical treatment (OMT), compared to OMT alone, over a one-year follow-up.

The study enrolled symptomatic patients (functional class II-IV) with TR higher than severe who were not surgical candidates. The primary endpoint was a clinical composite that included the occurrence of a cardiovascular event (hospitalization or death), changes in functional class (FC), and patient-reported symptoms (patient global assessment, PGA).

Secondary endpoints included changes in regurgitation, quality of life according to the Kansas City Cardiomyopathy Questionnaire (KCCQ), major adverse events (MAE), and safety events.

At one year of follow-up, 74.1% of the T-TEER group showed improvement in the primary endpoint, compared to 40.6% in the OMT group (Better Rank 0.67; 95% confidence interval [CI] 0.61-0.72; p<0.001).

Read also: ESC 2024 | MATERHORN Trial: Transcatheter vs. Surgical Mitral Repair in Patients with Heart Failure and Secondary Mitral Regurgitation.

In conclusion, the authors highlighted that T-TEER therapy significantly and safely improved clinical events in patients with severe symptomatic TR.

Presented by Erwan Donal at the Hot-Line Sessions, ESC Congress 2024, August 30-September 2, London, England.  


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...